Company intelligence / Profile preview

Genchain Biotech

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Genchain Biosciences is a clinical-stage biotechnology company specializing in the development of next-generation gene therapies. Based in Suzhou, China, the company leverages its proprietary AAV (Adeno-associated virus) platform to create treatments for rare genetic disorders. Its lead program, GC101, is an AAV-based gene therapy for Hemophilia B that has entered clinical trials. Genchain also maintains a robust pipeline targeting metabolic and neuromuscular diseases, including Pompe disease and Fabry disease. The company is backed by prominent venture capital firms such as Qiming Venture Partners and IDG Capital.

Therapeutic areas: HematologyRare Diseases
Modalities: Gene therapyAAV vector
Industry: Biotech

Beyond the preview

Go deeper on Genchain Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genchain Biotech.

Explore the full profile